We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 221-240 of 293 results
  1. Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma

    ERBB2 (HER-2/ neu ) amplification and/or overexpression are associated with poor prognosis in node-positive breast carcinoma. Its prognostic value in...

    Jérôme Couturier, Anne Vincent-Salomon, ... Xavier Sastre-Garau in Modern Pathology
    Article 01 November 2000
  2. Pathologie und Molekularbiologie bösartiger pulmonaler Tumoren

    Therapy and prognosis of lung cancer depend crucially on tumor size, tumor stage, and the histomorphological tumor type at the time of primary...

    T. Wiethege, K. Junker, ... K.-M. Müller in Der Pathologe
    Article 01 November 2000
  3. Development of a cancer vaccine: peptides, proteins, and DNA

    Genetic changes leading to protooncogene activation qualitatively and/or quantitatively alter their gene products and are exclusively or largely...

    Hiroshi Shiku, Lijie Wang, ... Hideo Nakamura in Cancer Chemotherapy and Pharmacology
    Article 01 July 2000
  4. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study

    It is generally thought that future advances in the treatment and cure of breast cancer patients will be made possible through a deeper understanding...

    Annalisa Volpi, Franca De Paola, ... Dino Amadori in Breast Cancer Research and Treatment
    Article 01 October 2000
  5. Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications

    Human papillomaviruses (HPVs) are the major aetiological agents of cervical carcinoma. In this review, epidemiological and molecular data are...

    Karin Milde-Langosch, Sabine Riethdorf, T. Löning in Virchows Archiv
    Article 01 September 2000
  6. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies

    Poly(ethylene glycol) (PEG) modification of substances with antitumor activity was shown to enhance penetration into growing solid tumors and extend...

    Esther Hurwitz, Leah N. Klapper, ... Michael Sela in Cancer Immunology, Immunotherapy
    Article 01 June 2000
  7. Bone marrow “micrometastases” of epithelial tumors: detection and clinical relevance

    The detection and elimination of “micrometastases” or, more precisely, isolated disseminated tumor cells or minimal residual disease is one of the...

    Peter Müller, Günter Schlimok in Journal of Cancer Research and Clinical Oncology
    Article 01 October 2000
  8. Ras activation in human breast cancer

    Genetic ras mutations are infrequent in breast cancer but Ras may be pathologically activated in breast cancer by overexpression of growth factor...

    Friederike C. von Lintig, Anna D. Dreilinger, ... Gerry R. Boss in Breast Cancer Research and Treatment
    Article 01 July 2000
  9. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis

    The interaction between the erbB tyrosine kinase receptors and their ligands plays an important role in tumor growth via the regulation of autocrine...

    Lily Yen, **ao-Li You, ... Moulay A Alaoui-Jamali in Oncogene
    Article 21 July 2000
  10. The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice

    HER-2/neu is overexpressed on a variety of human adenocarcinomas and overexpression has been associated with a poor prognosis. For this reason, HER-2...

    Birgitta Clinchy, Adi Gazdar, ... Ellen S. Vitetta in Breast Cancer Research and Treatment
    Article 01 June 2000
  11. Prognostic Significance of Immunohistochemically Localized Biomarkers in Stage II and Stage III Breast Cancer: A Multivariate Analysis

    Background: The aim was to investigate the expression of a panel of biomarkers such as prolactin (PRL), p53, Bcl-2, c-erb B2, Ki-67, CD44, and factor...

    Jyotsna M. Bhatavdekar, Devendra D. Patel, ... Trupti I. Trivedi in Annals of Surgical Oncology
    Article 01 May 2000
  12. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival

    Background/aims: The family of erbB receptors includes four transmembrane glycoproteins with tyrosine kinase activity. These receptors are widely...

    Sanja Kapitanović, Senka Radošević, ... Radan Spaventi in Journal of Cancer Research and Clinical Oncology
    Article 01 March 2000
  13. Prognostic significance of c-erb B-2 protein status using an enzyme immunoassay in breast cancer

    Background. The prognostic significance of c-erb B-2 in breast cancer remains controversial. The aim of this study was to determine the practical...

    E. Shin, Y. Takatsuka, ... N. Kikkawa in International Journal of Clinical Oncology
    Article 01 February 2000
  14. Docetaxel

    Abstract

    Docetaxel, a semisynthetic member of the taxoid class of antineoplastic agents, is effective in the treatment of patients with advanced...

    David P. Figgitt, Lynda R. Wiseman in Drugs
    Article 01 March 2000
  15. Growth Factors in Gliomas Revisited

    ¶ Overexpression or untimely expression of wild-type or mutated protein growth factors and their receptors is associated with the biology of...

    W. Hamel, M. Westphal in Acta Neurochirurgica
    Article 01 February 2000
  16. Keyword Index – Volume 18

    Article 04 January 2000
  17. The ErbB Receptors as Targets for Breast Cancer Therapy

    Breast carcinomas express high levels of ErbBreceptors and their ligands, and their overexpressionhas been associated with a more aggressive...

    Joan Albanell, Jose Baselga in Journal of Mammary Gland Biology and Neoplasia
    Article 01 October 1999
  18. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support

    C-erbB-2/HER-2 (designated HER-2) is overexpressed in both primary and metastatic breast cancer and predicts poor prognosis. We investigated the...

    M Bewick, T Chadderton, ... S Glück in Bone Marrow Transplantation
    Article 25 August 1999
Did you find what you were looking for? Share feedback.